← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest quality evidence only (79)Meta-analysis (20)Treatment guideline (4)Phase 3 study (27)Randomized trial (14)Systematic review (14)Clinical trial (677)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications and studies (1942)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort. (2025/11/28) ♡
• Impact of HCV cure on systemic inflammation and bone density, quality, and turnover. (2025/11/28) ♡
• Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis. (2025/11/27) ♡
• A novel scoring system to identify patients at low risk for hepatocellular carcinoma five years after DAA-induced sustained virological response: a retrospective cohort study. (2025/11/26) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study. (2025/11/21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Evaluation of portal venous flow velocity before and after direct acting antiviral therapy in chronic hepatitis C: A cohort study. (2025/11/21) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Group-based telehealth stress management-lifestyle interventions are feasible for patients with chronic liver disease. (2025/11/20) ♡
• The Effect of Anti-Viral Treatment of HCV Infection on Outcomes of Renal Transplant Patients with Chronic HCV Infection: A Real-World Cohort Study. (2025/11/20) ♡
• Comparative analysis of non-invasive fibrosis markers: Insights from chronic HBV, HBV+HDV, and HCV infections. (2025/11/19) ♡
• A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. (2025/11/18) ♡
• Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study. (2025/11/18) ♡
• Incidence and delayed diagnosis of hepatitis C: unexpected findings in times of elimination. (2025/11/17) ♡
• Bioinformatics Analysis of Persistent Dysregulated Expression of Genes Involved in HCV-Induced Neurological Disorders and Liver Injuries After DAA Treatment Through Weighted Gene Co-Expression Network Analysis. (2025/11/16) ♡
• Evolution of Liver Fibrosis in Romanian HCV Patients Following Treatment with Direct-Acting Antivirals. (2025/11/16) ♡
• Latent TB treatment outcomes in patients with chronic liver disease: A retrospective cohort study. (2025/11/15) ♡
• Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: a cross-sectional study. (2025/11/14) ♡
• Impact of HIV co-infection on liver fibrosis regression after HCV treatment. (2025/11/14) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co-infection: a systematic review and meta-analysis. (2025/11/13) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Challenges in the Diagnosis of Autoimmune Hepatitis in Patients With Chronic Viral Hepatitis C: A Case Series and Review of the Literature. (2025/11/13) ♡
• Exploring the liver microenvironment following successful therapy for HCV: gene expression profiling and residual T cell infiltration. (2025/11/10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Risk factors for virological relapse and long-term efficacy of direct-acting antiviral agents in chronic hepatitis C infection: Impact of HIV coinfection and renal function changes. (2025/11/07) ♡
• Pancreatic Ductal Adenocarcinoma After Hepatitis C Infection. (2025/11/03) ♡
• Prevalence and predictors of cirrhosis and portal hypertension in the United States. (2025/11/01) ♡
• High rate of HCV reinfection and the efficacy of standard regimens in men who have sex with men living with HIV. (2025/11/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. The association of direct-acting antiviral therapy with health care utilization and costs in patients with chronic hepatitis C virus infection: A systematic review of real-world studies in the United States. (2025/11/01) ♡
• Association of ANGPT2 and NOS3 Gene Variants With Esophageal Variceal Progression in HCV-Induced Cirrhosis. (2025/11/01) ♡
• Solute Carrier Gene Polymorphism (SLC29A1) in Relation to Treatment Outcome and Hematological Changes in Chronic Hepatitis C Patients Treated With Direct Acting Antivirals Plus Ribavirin. (2025/11/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial. (2025/11/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Novel evidence on the management of HCV-associated glomerular disease. (2025/11/01) ♡
• Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1. (2025/10/31) ♡
• Deep Sequencing Analysis of Hepatitis C Virus Subtypes and Resistance-Associated Substitutions in Genotype 4 Patients Resistant to Direct-Acting Antiviral (DAA) Treatment in Egypt. (2025/10/31) ♡
• Assessing the knowledge, attitudes, and psychological health of people who use drugs towards Hepatitis C: a cross-sectional study. (2025/10/31) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Direct-acting antiviral treatment impact on glycemic control in HCV-infected T2DM patients: An observational study with Mendelian randomization analysis. (2025/10/31) ♡
• Advances in clinical application on nursing intervention for ribavirin-associated adverse events. (2025/10/28) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals. (2025/10/27) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes. (2025/10/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Recent Advances in the Treatment of Chronic Hepatitis C]. (2025/10/25) ♡
• Intermediate-term risk of cardiac allograft vasculopathy following heart transplantation from hepatitis C viremic donors in the era of direct-acting antiviral therapy. (2025/10/25) ♡
• B cell transcriptomics reveals lasting dysregulation and rapid decline of protective memory after hepatitis C cure. (2025/10/24) ♡
• A Novel Municipal-Level Approach to Uncover the Hidden Burden of Hepatitis C: A Replicable Model for National Elimination Strategies. (2025/10/19) ♡
• The causal relationship between vitamin D deficiency and chronic hepatitis: A 2-sample Mendelian randomization approach. (2025/10/10) ♡
• Plasma Fibulin-5 as a Novel Marker for Advanced Fibrosis in Chronic Hepatitis C. (2025/10/10) ♡
• Understanding the cascade of care and predictors of treatment success among patients with hepatitis C - A prospective study at a tertiary care center in India. (2025/10/06) ♡
• Quantifying the Contribution of Viral Hepatitis Control Policies and Improvement of Hepatitis C Treatment in Japan during 2000-2030 based on Simulation Modelling. (2025/10/01) ♡
• Association of IFNL4 and IFITM3 Genetic Variants with Susceptibility to HCV-Related Liver Cirrhosis and Hepatocellular Carcinoma. (2025/10/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis. (2025/09/26) ♡
• Iron Metabolism Genes Shape the Course of Liver Fibrosis in Chronic Hepatitis C: From Disease Progression to Reversal After Direct-Acting Antivirals Treatment. (2025/09/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. State-of-the-Art Review: Hepatitis C. (2025/09/16) ♡
• Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy. (2025/09/15) ♡
• Prevalence of neurodevelopmental disorders in children with chronic hepatitis C in British Columbia. (2025/09/11) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.